stockrow
Saturday 7 November 2026
Export GNLX’s income statement to Excel — free account
Genelux Corporation
GNLX Healthcare Biotechnology
Genelux Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8,000.00, roughly unchanged from fiscal 2024.
- EPS
- −5.00%
- Free cash flow
- −11.2%
Quarter to June 2026, against a year earlier
1.97
0.15
+8.24%
Follow GNLX
Alert me
Genelux Corporation (GNLX) P/E ratio
Genelux Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2024 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GNLX Genelux Corporation | n/m |
| EQ Equillium, Inc. compare | n/m |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | n/m |
| VTVT vTv Therapeutics Inc. compare | n/m |
| MIST Milestone Pharmaceuticals Inc. compare | n/m |
| KZIA Novogen Limited compare | n/m |
| ATRA Atara Biotherapeutics, Inc. compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| RLYB Rallybio Corporation compare | 3.3× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)